Equiti Group Expands Platform Offering, Adds MetaTrader 5

Equiti Group, one of the leading providers of multi-asset financial products and online trading technology, announced the expansion of its offering through the addition of MetaTrader 5, a well-known multi-asset trading platform, today.

MT5 is one of the most popular trading platforms in the market. Due to its efficient features like quick processing time, copy trading and a wide range of technical indicators, MetaTrader 5 gained traction among traders around the world.

Iskandar Najjar, the CEO of Equiti Group, called the latest addition of MT5 an important step towards the achievement of Equiti’s growth targets in 2022.

"The addition of MetaTrader 5 to our range of trading platforms is one of the many ways we are expanding our offering to provide an advanced trading experience to our clients. MetaTrader 5 will enable our growth plans throughout 2022 and support thousands of new financial instruments including fractional shares and ETFs while offering superior trading features,” Najjar said.

Since the start of 2021, Equiti Group has expanded its product offering significantly to support clients through a broad range of trading options.

Features

The new addition will facilitate the clients of Equiti Group with different features, including access to impressive analytics tools. Moreover, users will be able to access several charts along with 21 available timeframes.

Christoforos Theodoulou, the Head of Global Business at MetaQuotes, said: "We are pleased that Equiti Group has chosen MetaTrader 5. It shows their dynamic approach to growing and adapting to market trends, aimed at providing the best tools and products to their global clients for an optimal trading experience."

In the past few months, Equiti Group announced several appointments to accelerate its global growth. In January this year, Gaurang Desai, the former Chief Executive Officer at the Dubai Gold and Commodities Exchange (DGCX Group), joined Equiti Group as the Managing Director of Strategy.